Signal transduction and activator of transcription 3(STAT3) signaling is constitutively activated in various tumors, and is involved in cell survival and proliferation during oncogenesis. There are few reports, however, on the role of STAT3 signaling in gastric cancer. The aim of the present study was to clarify the role of STAT3 signaling in apoptosis and cellular proliferation in gastric cancer. Here we reported that STAT3 was constitutively activated in various human gastric cancer cells and its inhibition by ectopic dominant-negative STAT3 or Janus kinase inhibitor, tyrphostin AG490, induced apoptosis. Furthermore, STAT3 inhibition markedly decreased survivin expression, and forced expression of survivin rescued AGS cells from apoptosis induced by STAT3 inhibition. Although some reports demonstrated that the PI3K/Akt pathway regulates survivin expression, inhibition of the PI3K/Akt pathway did not affect survivin expression in AGS and MKN1 cells. Finally, activated form of STAT3, Tyr-705 phospho-stat3, was found in the nucleus of cancer cells in 11 of 40 (27.5%) human gastric cancer specimens. These findings suggest that constitutively activated STAT3 signaling supports gastric cancer cell survival in association with survivin expression.
Introduction
Signal transduction and activator of transcription 3 (STAT3) was identified originally as a DNA-binding protein that responds to stimulation by epidermal growth factor and interleukin-6 (Akira et al., 1994; Zhong et al., 1994b) , and has an important role in their signaling (Ruff-Jamison et al., 1994; Zhong et al., 1994a, b) . Similar to other STATs, STAT3 is activated by phosphorylation of a single tyrosine residue (Tyr705) by Janus kinase in response to cytokine stimulation, and dimerizes via a reciprocal -SH2 phospho-tyrosine interaction (Darnell, 1997) . The dimeric STAT3 translocates to the nucleus, where it binds to defined DNA elements within the promoter region of target genes and activates their transcription (Horvath et al., 1995; Darnell, 1997; Sasse et al., 1997) . In physiologic conditions, the duration of STAT3 activation is temporary, and usually lasting from a few minutes to several hours (Bromberg, 2001) . In contrast, in many kinds of human tumors, STAT3 is constitutively activated and contributes to oncogenesis by both preventing apoptosis and enhancing cell proliferation (Bowman et al., 2000; Song and Grandis, 2000; Burke et al., 2001; Kube et al., 2001; Buettner et al., 2002; Mora et al., 2002) . We previously reported differentiation-inducing factor-1, which is a chlorinated hexaphenone isolated from Dictyostelium, inhibits gastric cancer cell proliferation by blockade of STAT3 signaling (Kanai et al., 2003) . However, little is known regarding the role of STAT3 signaling in gastric cancer.
Activation of STAT3 signaling upregulates the expression of various genes involved in cell survival and proliferation such as bcl-x, bcl-2, mcl-1, cyclin D1, and c-myc (Bromberg et al., 1999; Burke et al., 2001; Rahaman et al., 2002; Real et al., 2002) . In the present study, therefore, we examined whether STAT3 signaling is constitutively activated in gastric cancer cells, and investigated the role of STAT3 signaling in cell survival and proliferation. Here we demonstrate that STAT3 is constitutively activated in various gastric cancer cells, and its inhibition induces apoptosis in association with a reduction of survivin expression.
Results

STAT3 was constitutively activated in various gastric cancer cells
To examine STAT3 activation in gastric cancer cells, cell lysates were made from gastric cancer cell lines, AGS, MKN1, MKN7, MKN28, KATOIII, and HCG 27. Cell lysates were immunoprecipitated by anti-phospho-specific tyrosine antibody, and Western blotting was performed using anti-STAT3 antibody. Phosphorylated STAT3 (p-STAT3) protein was abundantly detected in five of six cell lines except KATOIII (Figure 1a) . Phosphorylated STAT3 protein level of KATOIII was very low. Western blotting using anti-phospho-specific STAT3 (Tyr705) antibody was also carried out. Tyr-705-phospho-STAT3 is taken as an active form of STAT3. STAT3 was constitutively phosphorylated on Tyr705 in five out of six cell lines except KATOIII (Figure 1a) . Moreover, STAT3 DNA-binding activities in AGS, MKN1, and MKN7 cells were confirmed by EMSA. Stat3 DNA-binding activity was observed in these cell lines (Figure 1b) . To confirm that DNAbinding activity of STAT3 is specific, electrophoretic mobility shift assay (EMSA) was performed using stat3 mutant oligonucleotide in AGS cells and shifted band was not observed (Figure 1b, lane 5) . The results demonstrated that STAT3 was constitutively activated in various gastric cancer cell lines.
Dominant-negative STAT3 and AG490 inhibited STAT3 activation in AGS, MKN1, and MKN7 cells
To examine the effects of dominant-negative STAT3 and Janus kinase inhibitor tyrphostin AG490, cell lysates were immunoprecipitated by anti-phospho-specific tyrosine antibody and Western blotting was performed. EMSA was also carried out. Tyrosinephosphorylated STAT3 protein level was markedly reduced by 20 mM of AG490 in AGS cells at 48 h (Figure 2a) . In MKN1 and MKN7 cells, tyrosinephosphorylated STAT3 protein levels were markedly decreased by 40 mM of AG490 at 48 h (Figure 2a) . Furthermore, 40 mM of AG490 inhibited the DNAbinding activity of STAT3 after 48 h incubation in AGS, MKN1, and MKN7 cells (Figure 2b, lanes 4, 6, 9) . Dominant-negative STAT3 also inhibited the DNAbinding activity of STAT3 at 48 h in AGS cells ( Figure 2b , lane 2).
AG490 inhibited proliferation of AGS, MKN1, and MKN7 cells
We then investigated whether inhibition of STAT3 signaling affects cell proliferation of gastric cancer cells. Twenty or 40 mM of AG490 inhibited proliferation of AGS, MKN1, and MKN7 cells (Figure 3) . At 72 h, 40 mM of AG490 inhibited cellular proliferation of AGS, MKN1, and MKN7 cells by 73.0, 66.9, and 64.0% compared with those of control cells, respectively. Although STAT3 was not strongly activated in KA-TOIII cells, 20 and 40 mM of AG490 inhibited proliferation by 14.4 and 23% compared with those of the control cells at 48 h, respectively (figure not shown). The data indicated that STAT3 signaling regulates proliferation of gastric cancer cells.
AG490 induced apoptosis of AGS, MKN1, and MKN7 cells
Next, to investigate whether inhibition of STAT3 signaling induces apoptosis, terminal deoxynucleotidyltransferase-mediated UTP end labeling (TUNEL) staining was performed after incubation in the presence of various doses of AG490. At 48 h, AG490 induced apoptosis in a dose-dependent manner in AGS, MKN1, and MKN7 cells (Figure 4a ). Moreover, 40 mM of AG490 induced apoptosis of 13.2% at 24 h, 28.5 at 48 h, and 37.0% of AGS cells at 72 h (Figure 4b ). Representative TUNEL staining of AGS cells incubated with the indicated doses of AG490 is shown in Figure 4c .
Inhibition of STAT3 decreased survivin protein expression in AGS, MKN1, and MKN7 cells
Western blotting was performed 48 h after incubation with AG490. At 48 h, AG490 reduced survivin protein expression in a dose-dependent manner in AGS and MKN1 cells (Figure 5a ). AG490 at 40 mM markedly reduced survivin expression from 24 h in AGS and from 12 h in MKN1 cells (Figure 5b) . In MKN7 cells, survivin expression was also reduced by 40 mM of AG490 (Figure 5c ). Moreover, dominant-negative STAT3 markedly decreased survivin protein expression at 48 h after transfection (Figure 5d ). Lysates from six gastric cancer cell lines were immunoprecipitated with anti-phospho-tyrosine-specific antibody, followed by Western blotting using anti-STAT3 antibody (upper panel). Lysates were also immunoblotted by antiphospho-specific-STAT3 (Tyr705) and anti-STAT3 antibody (middle and lower panels). (b) In AGS, MKN1, and MKN7 cells, a shifted band was observed in EMSA using radiolabeled STAT3 consensus oligonucleotide (lanes 1-3). A competitor assay was performed using specific cold probe at 20 Â the concentration of the labeled probe and nuclear extract from AGS cells (lane 4). The shifted band was not observed when using STAT3 mutant oligonucleotide and nuclear extract from AGS cells (lane 5)
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Inhibition of STAT3 decreased cyclin D1 protein expression in AGS, MKN1, and MKN7 cells
We also examined the effect of STAT3 inhibition on cyclin D1 and bcl-x protein expression using Western blotting. In AGS, MKN1, and MKN7 cells, 40 mM of AG490 also decreased cyclin D1 protein expression ( Figure 6a ). Dominant-negative STAT3 also decreased cyclin D1 protein expression ( Figure 6b ). AG490 at 40 mM decreased bcl-x protein expression in MKN1 cells; however, in AGS and MKN7 cells, 40 mM of AG490 did not affect bcl-x protein expression ( Figure 6a ). Dominant-negative STAT3 also did not change bcl-x protein expression in AGS cells ( Figure 6b ). In serum-free conditions, other bcl-2 family proteins, bcl-2 and mcl-1, were not detected by Western blotting, although 40 mM of AG490 did not affect bcl-x and mcl-1 mRNA expression level in RT-PCR experiments (data not shown).
Forced expression of survivin rescued AGS cells from apoptosis induced by STAT3 inhibition
To determine whether reduction of survivin is responsible for AGS cell apoptosis induced by STAT3 inhibition, myc-tagged-survivin-transfected cells as well as mock vector-transfected cells were incubated with AG490. At 8 h after the transfection, transfected cells were incubated with 40 mM of AG490 in growth medium without serum. Expression of endogenous survivin protein disappeared in both cells after 48 h incubation with 40 mM of AG490' however, myc-survivin was retained in myc-tagged-survivin-transfected cells ( Figure 7a ). Forced expression of survivin rendered significantly less sensitive to AG490 in AGS cell proliferation (Figure 7b ). At 48 h, the growth rate of mock vector-transfected cells was 32.5%' on the other hand, the growth rate of survivin-transfected cells was 62.1% compared with that of mock-vector-transfected cells incubated without AG490. Furthermore, after 48 h incubation with 40 mM of AG490, forced expression of survivin significantly lowered apoptotic cell levels compared with mock-vector-transfected cells (Figure 7c ). TUNEL-positive cells were 54.0% and 34.0% in mock-transfected cells and survivin-transfected cells, respectively.
Inhibition of PI3K-Akt pathway did not affect survivin protein expression in AGS and MKN1 cells
Several studies report that survivin expression is induced via the PI-3 kinase/Akt-dependent pathway (Papapetropoulos et al., 2000; Tran et al., 2002) , and that an active form of Akt, Ser473-phosphorylated Akt, is observed in gastric cancer cells (Izuishi et al., 2000; Kanai et al., 2003) . To examine whether survivin expression is regulated by the PI-3 kinase/Akt-dependent pathway in AGS and MKN1 cells, Western blotting was performed. Protein was extracted from AGS and MKN1 cells incubated in the presence or absence of 500 nM of PI-3 kinase inhibitor wortmannin for 24 h. Interestingly, strong expression of survivin protein was not changed by wortmannin treatment, although the active form of Akt disappeared (Figure 8 ).
Tyr-705-phospho-STAT3 was found in the nucleus of cancer cells in human gastric cancer specimens
Tyr-705-phospho-STAT3 is taken as an active form of STAT3 and it translocates to the nucleus. Immunohistochemistry showed Tyr-705-phospho-STAT3 localized to the nucleus of cancer cells in 11 of 40 (27.5%) human gastric cancer specimens. Representative immunohistochemistry is shown in Figure 9 .
Discussion
Unlike in normal cells and tissues, constitutively activated STATs are detected in a wide variety of human tumors. Such aberrant activation of STATs, especially STAT3, is often associated with cell survival, proliferation, and transformation (Bromberg et al., 1998 (Bromberg et al., , 1999 Buettner et al., 2002) . In the present study, by examining not only phosphorylation of Tyr705 but also the DNA-binding activity of STAT3, we demonstrated that STAT3 is constitutively activated in various human gastric cancer cells. We also showed that blockade of STAT3 signaling induces apoptosis and growth inhibition of AGS, MKN1, and MKN7 cells. Although STAT3 was not strongly activated in KA-TOIII cells, AG490 inhibited proliferation slightly. Since STAT3 is temporarily activated in physiological conditions, these results were reasonable. Moreover, activated form of STAT3 was found in the nucleus of cancer cells in 11 of 40 (27.5%) human gastric cancer specimens. Athough 11 of 40 (27.5%) are not very frequent, molecular alteration of gastric cancer is various: for example, p53 LOH/mutation 20-38%; cyclin E overexpression 10-20% (Werner et al., 2001) . Thus, as in other cancer cells, constitutive activation of STAT3 appears to have an important role in the survival of some kinds of gastric cancer cells by suppressing apoptosis and enhancing cell proliferation. What are the mechanisms underlying STAT3-induced survival and proliferation of gastric cancer cells? Activation of STAT3 signaling is reported to upregulate the expression of various genes involved in cell survival and proliferation, such as the bcl-2 family, cyclin D1, and c-myc (Bromberg et al., 1999; Burke et al., 2001; Rahaman et al., 2002; Real et al., 2002) . In the present study, however, induction of apoptosis elicited by STAT3 inhibition was not associated with downregulation of bcl-2 family expression in AGS and MKN7 cells. Thus, bcl-2 family might not always be involved in the STAT3-induced inhibition of apoptosis in gastric cancer cells. Instead, a remarkable finding in this study was that expression of an inhibitor of apoptosis protein family member survivin was markedly reduced by STAT3 inhibition and that forced expression of survivin rescued AGS cells from apoptosis induced by AG490. Survivin expression is undetectable or at very low levels in normal adult tissues and is overexpressed in most human tumors including gastric cancer (Ambrosini et al., 1997; Konno et al., 2000; Fukuda and Pelus, 2001; Gianani et al., 2001; Altieri, 2003) . Patients whose tumors express survivin have a decreased survival rate (Kawasaki et al., 1998; Monzo et al., 1999; Ikeguchi and Kaibara, 2002) , increased rate of recurrence (Swana et al., 1999) , and resistance to therapy (Tran et al., 2002; signaling has been reported to induce apoptosis in association with reduction of survivin expression without down-regulation of bcl-2 family proteins in primary effusion lymphoma cells (Aoki et al., 2003) . Taken together, STAT3 might be a main regulator of survivin expression in gastric cancer cells and involved in tumor progression through regulation of survivin expression.
In the present study, inhibition of STAT3 signaling reduced cyclin D1 expression. Since cyclin D1 has an important role in the G1 to G2 phase transition, antiproliferative effect by blockade of STAT3 signaling might be partially attributed to reduction of cyclin D1 expression. Moreover, survivin expresses in a cell cycledependent manner (Li et al., 1998) . Therefore, reduced In the present study, we did not clarify the upstream of STAT3 activation. In most tumors, the cause of persistent activation of STAT3 is not known. In some myeloma cells and prostate cancer cells, however, constitutively activated STAT3 signaling is due to abnormally regulated IL6-JAK signaling in an autocrine or paracrine manner (Catlett-Falcone et al., 1999; Giri et al., 2001; Bisping et al., 2003) . In the present study, IL6 did not affect survivin expression in AGS and MKN1 cells (data not shown). Further studies are needed to clarify the cause of constitutive activation of STAT3 signaling in gastric cancer cells.
In conclusion, STAT3 is constitutively activated in various human gastric cancer cell lines and specimens, and blockade of STAT3 signaling induced apoptosis with decreased survivin expression. Therefore, inhibition of STAT3 signaling and the following reduction of survivin expression might provide a novel therapeutic target of gastric cancer.
Materials and methods
Antibodies and other reagents
Janus kinase inhibitor, AG490, was purchased from Wako Pure Chemical Industries Ltd (Osaka, Japan). Anti-STAT3, bcl-x, bcl-2, mcl-1, and cyclin D1 antibodies were obtained from BD Sciences (San Jose, CA, USA). Anti-b-actin antibody and wortmannin were purchased from Sigma Chemical Co. (St Louis, MO, USA). Anti-phospho-specific STAT3 (Tyr705), Akt, and phospho-specific Akt (Ser473) antibodies were obtained from New England Biolabs (Beverly, MA, USA). Anti-survivin antibody was obtained from Alpha Diagnostic International (San Antonio, TX, USA).
Cell culture
A human gastric cancer cell line, AGS, was maintained in Ham's F12 medium containing 10% fetal bovine serum (FBS), 100 mg/ml streptomycin, and 100 IU/ml penicillin in 5% CO 2 at 371C. MKN1, MKN7, MKN28, and KATOIII were cultured in RPMI 1640 medium supplemented with 10% FBS. HCG27 were cultured in MEM medium supplemented with 10% FBS.
Cell proliferation assay
For cell proliferation assays, AGS and MKN7 cells were seeded at a density of 2. 
Western blotting
Cells were lysed in 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40 (NP-40), 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 2 MoO 4 , 10 mM/ml aprotinin, and 10 mM/ml leupeptin. Equal amounts of protein extracts were fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to immobilin-P membrane (Millipore Corporation, Bedford, MA, USA). The membranes were incubated with anti-survivin, bcl-x, and cyclin D1 antibodies for 1 h at 371C and 12 h at 41C, or with anti-STAT3, phospho-specific-STAT3 (Tyr705), and b-actin antibodies for 1 h at 371C, and then incubated with peroxidaseconjugated secondary antibodies for 1 h at 371C. Proteins were detected by the enhanced chemiluminescence (ECL pbs) system (Amersham Pharmacia Biotech, Buckinghamshire, UK). The same experiments were performed three times and representative data are shown.
Immunoprecipitation
Cells were lysed in lysis buffer described in Western blotting, and then incubated with anti-phospho-specific-tyrosine antibody (Santa Cruz Biotechnology, CA, USA) immobilized on protein A-sapharose (Santa Cruz Biotechnology, CA, USA) at 41C overnight with constant rotation. Immunoprecipitates were washed with PBS five times and suspended in SDS sample buffer, then boiled and analysed by Western blotting using anti-STAT3 antibody.
Electrophoretic mobility shift assay
After 48 h incubation with AG490 or 48 h after transient transfection of dominant-negative STAT3, nuclear extracts were prepared and incubated in binding buffer (10 mM TrisHCl, 0.5 mM DTT, 0.5 mM EDTA, 4% glycerol, 1 mM MgCl 2 , 50 mM NaCl, 500 ng/ml poly-dldC) at room temperature for 20 min with 32 P-labeled consensus oligonucleotide (5 0 -GATCCTTCTGGGAATTCCTAGATC-3 0 ) as previously described (Vinkemeier et al., 1996) . Samples were then electrophoresed through a 6% polyacrylamide gel, dried, and subjected to autoradiography. Competitor assays were performed using a specific cold probe at 20 Â the concentration of the labeled probe. To confirm that DNA-binding activity of STAT3 is specific, EMSA was performed using stat3 mutant oligonucleotide (5 0 -GATCCTTCTGG CCGTCCTAGATC-3 0 ). The same experiments were performed three times and representative data are shown.
Transfections
The dominant-negative STAT3 (phenylalanine substitution at Tyr705) vector was created using the in vitro mutagenesis primer set (Takara Biomedicals, Shiga, Japan) as previously described (Nakajima et al., 1996) . Dominant-negative STAT3 was inserted into the NotI site of the pOPRSVI/MCS vector (Stratagene, La Jolla, CA, USA). Myc-tagged survivin vector was created as described previously (Marusawa et al., 2003) . Transient transfection to AGS cells was performed using Lipofectamin 2000 (Invitrogen) according to the manufacturer's instructions. At the same time, mock vectors were also transfected to AGS cells. The efficiency of transfection was confirmed by immunohistochemical detection of b-galactosidase after transfection of the vector expressing Escherichia coli b-galactosidase and the efficiency was about 85%.
Immunohistochemistry
A total of 40 gastric cancer specimens were fixed in 10% formalin, embedded in paraffin, and sectioned in 5 mm thickness. For immunohistochemistry, the sections were deparaffinized, rehydrated, incubated with 3% H 2 O 2 in methanol for 20 min, and subjected to heat-induced antigen retrieval by boiling for 10 min in 0.01 M sodium citrate. Subsequently, the specimens were blocked with normal goat serum for 30 min and incubated for 2.5 h at room temperature with anti-phospho-specific STAT3 (Tyr705) antibody (1 : 100) (New England Biolabs). The immune complex was visualized with the Vectastain Elite Kit (Vector Laboratories, Burlingame, CA, USA), according to the manufacturer's protocol.
